Neuland Laboratories Limited (NEULANDLAB) Net Income 2023–2026

Name: Neuland Laboratories Limited (NEULANDLAB) net income history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Neuland Laboratories Limited annual net income for fiscal 2026 was ₹3.6 billion, an increase of 39.9% from ₹2.6 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

NEULANDLAB Annual Net Income

Net Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Net Income	₹3.6B	₹2.6B	₹3.0B	₹1.6B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NEULANDLAB Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Net Income	₹1.5B	₹2.1B	₹406M	₹968M	₹139M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

AJANTPHARM Net Income — Ajanta Pharma Limited
EMCURE Net Income — Emcure Pharmaceuticals Limited
WOCKPHARMA Net Income — Wockhardt Limited
1276 Net Income — Jiangsu Hengrui Pharmaceuticals Co.,Ltd
4540 Net Income — Tsumura & Co.
PPLPHARMA Net Income — Piramal Pharma Limited

More NEULANDLAB metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All NEULANDLAB financial statements → Interactive NEULANDLAB charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.